Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volixibat in Intrahepatic Cholestasis of Pregnancy (OHANA)
NCT04718961Phase 2Terminated
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of volixibat in intrahepatic cholestasis of pregnancy (ICP) (4 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Safety and Tolerability of Volixibat up to 21 weeks. Started Jan 2021; status: terminated.
02
Drugs
volixibat
03
Conditions
intrahepatic cholestasis of pregnancy (ICP)
Beyond the preview
Go deeper on NCT04718961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718961.